Pioneering Gene Therapy Restores Hearing in Deaf Toddler

A groundbreaking trial in the UK marks a potential shift in treatment for genetic deafness, showcasing significant hearing improvement.

18-month-old Opal Sandy experienced near-normal hearing restoration following a new gene therapy trial targeting auditory neuropathy.
The therapy, developed by biotech firm Regeneron, introduces a working gene directly to the affected ear.
Opal's successful treatment could pave the way for new gene therapies aimed at other genetic-related hearing conditions.
The trial has sparked hope among families and could represent a shift away from traditional cochlear implants.
Further trials are planned, with up to 18 children from the UK, Spain, and the US participating over the next five years.